Search: WFRF:(Lammert F)
> Örebro University >
Evaluating the cost...
Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands
-
- Valentine, W. J. (author)
- Ossian Health Economics and Communications GmbH, Basel, Switzerland
-
- Jendle, Johan, 1963- (author)
- Örebro universitet,Institutionen för medicinska vetenskaper
-
- Saraheimo, M. (author)
- Folkhälsan Research Centre, Helsinki University, Helsinki, Finland
-
show more...
-
- Thorsteinsson, B. (author)
- Department of Cardiology and Endocrinology, Hillerød Hospital, Hillerød, Denmark; Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
-
- Pollock, R. F. (author)
- Ossian Health Economics and Communications GmbH, Basel, Switzerland
-
- Lammert, M. (author)
- Novo Nordisk Scandinavia, Copenhagen, Denmark
-
show less...
-
(creator_code:org_t)
- 2012-02-22
- 2012
- English.
-
In: Diabetic Medicine. - : Wiley-Blackwell Publishing Inc.. - 0742-3071 .- 1464-5491. ; 29:3, s. 303-312
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- AIMS: To estimate short-term cost-effectiveness of insulin detemir vs. NPH insulin based on the incidence of mild hypoglycaemia in subjects with Type 1 diabetes in Denmark, Sweden, Finland and the Netherlands.METHODS: A model was developed to evaluate cost-effectiveness based on mild (self-treated) hypoglycaemia and pharmacy costs over 1 year. Published rates of mild hypoglycaemia were used for NPH insulin and insulin detemir. Effectiveness was calculated in terms of quality-adjusted life expectancy. Pharmacy costs were accounted using published prices and defined daily doses for both insulins. Costs were expressed in 2010 euros (€).RESULTS: Treatment with insulin detemir was associated with fewer mild hypoglycaemic events than NPH insulin (mean rates of 26.3 vs. 35.5 events per person-year), leading to an improvement in mean quality-adjusted life expectancy of approximately 0.019 (0.030) quality-adjusted life years (standard deviation). Annual costs were € 573.55 (110.42) vs. € 332.76 (62.18) in Denmark for insulin detemir and NPH insulin, respectively. These values were € 545.79 (106.54) vs. € 306.12 (57.78) in Sweden, € 720.10 (140.74) vs. € 408.73 (78.61) in Finland and € 584.01 (109.47) vs. € 359.60 (64.84) in the Netherlands. Incremental cost-effectiveness ratios were approximately € 12,644 (Denmark), € 12,612 (Sweden), € 16,568 (Finland) and € 12,216 (the Netherlands) per quality-adjusted life year gained for insulin detemir vs. NPH insulin.CONCLUSIONS: Insulin detemir is likely to be cost-effective vs. NPH insulin in subjects with Type 1 diabetes in Denmark, Sweden, Finland and the Netherlands. Increased pharmacy costs with insulin detemir should not be a barrier to therapy based on these findings.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- analogues
- economics
- hypoglycaemia
- Type 1 diabetes
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database